Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) for the Treatment of Patients With Severe Community-Acquired Pneumonia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00084071

Enrollment

2136

Registered

2004-06-08

Start date

2004-05-31

Completion date

2008-07-31

Last updated

2020-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Brief summary

The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.

Interventions

DRUGTifacogin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Diagnosis of community-acquired pneumonia supported by additional clinical, radiological, and microbiological evidence * Pneumonia of sufficient severity to require ICU admission and management

Exclusion criteria

* Pregnancy * Weight over 150 kg * Patients at increased risk of bleeding * Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa * Treatment with heparin or anticipated need for heparin

Design outcomes

Primary

Measure	Time frame
Compare the effect of tifacogin vs placebo administration.	—

Countries

Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Malaysia, Netherlands, New Zealand, Peru, Singapore, South Africa, South Korea, Spain, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026